Harmony Biosciences Holdings

Harmony Biosciences Secures FDA Orphan Drug Designation for Pitolisant in Prader-Willi Syndrome Treatment

PLYMOUTH MEETING, PA — The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to Harmony Biosciences Holdings, Inc.’s (Nasdaq: HRMY) pitolisant for the treatment of Prader-Willi syndrome …

Harmony Biosciences Secures FDA Orphan Drug Designation for Pitolisant in Prader-Willi Syndrome Treatment Read More

Neuraptive Therapeutics

Neuraptive Therapeutics Earns FDA Orphan Drug Designation for Novel Peripheral Nerve Injury Treatment

WAYNE, PA — Neuraptive Therapeutics Inc. recently announced that its novel treatment for peripheral nerve injury, NTX-001, has received Orphan Drug Designation from the United States Food and Drug Administration …

Neuraptive Therapeutics Earns FDA Orphan Drug Designation for Novel Peripheral Nerve Injury Treatment Read More

Baudax Bio, Inc.

Marinus Pharmaceuticals

Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome

RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) announced that the U.S. Food and Drug Administration (FDA) recently granted orphan drug designation (ODD) to ganaxolone for the treatment of Lennox-Gastaut …

Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome Read More